What is the NF-κB pathway?
The NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway is a transcription-factor signalling cascade that regulates expression of genes involved in inflammation, immune response, cell survival, and cell proliferation. The published downstream mechanism for KPV anti-inflammatory pharmacology following PepT1-mediated intestinal-epithelial uptake.
What the research literature says
NF-κB is a family of transcription factors (RelA/p65, RelB, c-Rel, p50, p52) that exist as dimers held inactive in the cytoplasm by IκB inhibitor proteins. Activation by inflammatory stimuli triggers phosphorylation of IκB by the IKK kinase complex, leading to IκB degradation and release of active NF-κB dimers that translocate to the nucleus and drive transcription of pro-inflammatory genes.
KPV’s anti-inflammatory pharmacology operates through downstream NF-κB-pathway modulation following PepT1-mediated intestinal-epithelial uptake. The Dalmasso PepT1-uptake characterisation (PMID 18061177) and the Kannengiesser IBD-research work (PMID 18092346) established the framework. The Viennois colitis-associated cancer work characterised the integration with broader inflammatory-pathway pharmacology (PMID 27458604).
TB-500’s angiogenesis-research mechanism also involves Notch/NF-κB pathway engagement in limb-ischemia models per the Lv work (PMID 32945357), though through a different receptor-engagement pathway than KPV’s intestinal-uptake framework.
Why this matters in research context
The NF-κB pathway matters in peptide-research contexts as the downstream mechanism for KPV’s anti-inflammatory pharmacology and as a downstream contributor to TB-500’s limb-ischemia angiogenesis pharmacology. Researchers studying these compounds should account for NF-κB-axis engagement as a key intermediate readout in mechanism-anchored experimental designs.
Related compounds
- KPV 10mg — NF-κB modulation downstream of PepT1 uptake
- TB-500 10mg — Notch/NF-κB pathway in limb-ischemia angiogenesis
Related research questions
References
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134(1):166-178. [PMID 18061177]
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14(3):324-331. [PMID 18092346]
- Lv S et al. Thymosin-β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-κB pathway. Int J Mol Med 2020;46(4):1347-1358. [PMID 32945357]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.